Comparison osteopontin vs AFP for the diagnosis of HCC: A meta-analysis

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 6, 2014, Pages 706-714

  Wan, Hao Guang ^a   Xu, Hao ^a   Gu, Yu Ming ^a   Wang, Hui ^a   Xu, Wei ^a   Zu, Mao Heng ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; OSTEOPONTIN; BIOLOGICAL MARKER;

ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; MOLECULAR DIAGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TASK PERFORMANCE; BLOOD; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; LIVER NEOPLASMS;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; OSTEOPONTIN;

EID: 84919327318     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.06.008     Document Type: Article

References (28)

1. Malaguarnera G., Giordano M., Paladina I., Berretta M., Cappellani A., Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci 2010, 55:2744-2755.
2. Bertino G., Ardiri A., Malaguarnera M., Malaguarnera G., Bertino N., Calvagno G.S. Hepatocellualar carcinoma serum markers. Semin Oncol 2012, 39:410-433.
3. Umemura T., Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007, 37(Suppl.2):S95-S100.
4. Mao Y., Yang H., Xu H., Lu X., Sang X., Du S., et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010, 59:1687-1693.
5. Choi J.Y., Jung S.W., Kim H.Y., Kim M., Kim Y., Kim D.G., et al. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J Gastroenterol 2013, 19:339-346.
6. Sherman M., Peltekian K.M., Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995, 22:432-438.
7. Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology 1990, 12:1420-1432.
8. Johnson P.J. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001, 5:145-159.
9. Khalil A., Elgedawy J., Faramawi M., Elfert A., Salama I., Abbass A., et al. Plasma osteopontin level as a diagnostic marker of hepatocellular carcinoma in patients with radiological evidence of focal hepatic lesions. Tumor 2012, 99:100-107.
10. Whiting P., Rutjes A.W., Reitsma J.B., Bossuyt P.M., Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003, 3:25.
11. Whiting P.F., Weswood M.E., Rutjes A.W., Reitsma J.B., Bossuyt P.N., Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006, 6:9.
12. Leeflang M.M. Systematic reviews and meta-analyses of diagnostic test accuracy. Clin Microbiol Infect 2014, 20:105-113.
13. Harbord R.M., Whiting P., Sterne J.A.C., Egger M., Deeks J.J., Shang A., et al. An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. J Clin Epidemiol 2008, 61:1095-1103.
14. Zamora J., Abraira V., Muriel A., Khan K., Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006, 6:31.
15. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
16. Baker W.L., White C.M., Cappelleri J.C., Kluger J., Coleman C.I. Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract 2009, 63:1426-1434.
17. Peters J.L., Sutton A.J., Jones D.R., Abrams K.R., Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006, 295:676-680.
18. Zekri A-RN, Bahnassy A.A., Alam El-Din H.M., Morsy H.M., Shaarawy S., Moharram N.Z., et al. Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma. Oncol Rep 2011, 26:825-831.
19. Kim J., Ki S.S., Lee S.D., Han C.J., Kim Y.C., Park S.H., et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 2006, 101:2051-2059.
20. El-Din Bessa S.S., Elwan N.M., Suliman G.A., El-Shourbagy S.H. Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. Arch Med Res 2010, 41:541-547.
21. Abu El Makarem M.A., Abdel-Aleem A., Ali A., Saber R., Shatat M., Rahem D.A., et al. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann Hepatol 2011, 10:296-305.
22. Shang S., Plymoth A., Ge S., Feng Z., Rosen H.R., Sangrajrang S., et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012, 55:483-490.
23. Yang L., Rong W., Xiao T., Zhang Y., Xu B., Liu Y., et al. Secretory/releasing proteome-based identification of plasma biomarkers in HBV-associated hepatocellular carcinoma. Sci China Life Sci 2013, 56:638-646.
24. Xu Y., Wan Y., Zhang Y., Chen Y. Detected clinical significance of plasma osteopontin in patients with hepatocellular carcinoma. Chin J Cancer Prev Treat 2012, 19.
25. Salem M., Atti S.A., El Raziky M., Darweesh S.K., El Sharkawy M. Clinical significance of plasma osteopontin level as a biomarker of hepatocellular carcinoma. Gastroenterol Res 2013, 6:191-199.
26. Whiting P., Harbord R., Kleijnen J. No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Med Res Methodol 2005, 5:19.
27. Petitti D.B. Approaches to heterogeneity in meta-analysis. Stat Med 2001, 20:3625-3633.
28. Pepe M.S., Etzioni R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061.